Special Issue

Antimicrobial Peptides and How to Find Them

Message from the Guest Editor

The rise of multidrug-resistant microorganisms and the absence of new classical antibiotics have drawn attention to another class of antimicrobial molecules: antimicrobial peptides (AMPs). For decades, researchers have managed to develop anti-infective medicines from naturally occurring peptides. To date, more than ten peptide-based antibiotics are on the market (e.g., bacitracin, gramicidin, vancomycin, and others), and dozens are in clinical development. The sources for AMPs are highly diverse and include mammals, invertebrates, microorganisms, plants, and marine organisms. Today, bioinformatics tools are also employed in the design or amelioration of potent new AMPs using specific algorithms. In this Special Issue entitled “Antimicrobial Peptides: How to Find Them”, we invite publications on the search of novel antimicrobial peptides, based on either classical or modern methods, including predictions and the design of AMPs. Novel strategies focused on discovering AMPs against multidrug-resistant microorganisms are of particular interest in this Special Issue. Keywords: bioscreening; bioinformatics; antibacterial; antiviral; antifungal

Guest Editor

Dr. Ludger Ständker
Faculty of Medicine, Ulm University, Ulm, Germany

Deadline for manuscript submissions

closed (31 May 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/si/91160

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI